Xencor (NASDAQ:XNCR) Posts Earnings Results, Beats Estimates By $0.19 EPS

Xencor (NASDAQ:XNCR) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19, Zacks reports. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%.

Xencor Trading Up 5.1 %

Shares of XNCR traded up $0.74 during midday trading on Thursday, hitting $15.12. The stock had a trading volume of 400,519 shares, compared to its average volume of 495,164. The stock’s 50 day moving average is $19.79 and its 200 day moving average is $20.68. The firm has a market cap of $1.06 billion, a PE ratio of -4.74 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor has a 1 year low of $14.18 and a 1 year high of $27.24.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XNCR. Wedbush reissued an “outperform” rating and issued a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a report on Wednesday. JPMorgan Chase & Co. increased their target price on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Xencor has a consensus rating of “Moderate Buy” and an average target price of $34.88.

Insider Transactions at Xencor

In other news, Director Alan Bruce Montgomery sold 1,421 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the completion of the sale, the director now owns 9,140 shares in the company, valued at approximately $247,054.20. This represents a 13.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.23% of the company’s stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.